Drug General Information (ID: DDI1QRJ746)
Drug Name			Pravastatin		Drug Info		Dicoumarol		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Statins/Antihyperlipidemic Agents				Anticoagulants
Structure

Mechanism of Pravastatin-Dicoumarol Interaction (Severity Level: Minor)
Increased risk of bleeding Click to Show/Hide Mechanism Graph
Drug Name		Pravastatin				Dicoumarol
Mechanism		Potentiate the hypoprothrombinemic effect of vitamin K antagonist				Vitamin K antagonist
Key Mechanism Factor 1
		Factor Name		Bleeding
		Factor Description		Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc.
Mechanism Description		Increased risk of bleeding by the combination of Pravastatin and Dicoumarol

References
1	Jungnickel PW, Cantral KA, Maloley PA "Pravastatin: a new drug for the treatment of hypercholesterolemia." Clin Pharm 11 (1992): 677-89. [PMID: 1511541]
2	Pan HY "Clinical pharmacology of pravastatin, a selective inhibitor of HMg-CoA reductase." Eur J Clin Pharmacol 40 Suppl 1 (1991): s15-8. [PMID: 1904355]
3	Product Information. Pravachol (pravastatin). Bristol-Myers Squibb, Princeton, NJ.